<DOC>
	<DOCNO>NCT00002688</DOCNO>
	<brief_summary>RATIONALE : Some cancer become resistant chemotherapy drug . Combining cyclosporine chemotherapy may prevent resistance drug allow cancer cell kill . PURPOSE : Randomized phase II trial study effectiveness add cyclosporine combination chemotherapy treat patient relapsed refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Cyclosporine Combination Chemotherapy Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate whether addition cyclosporine ( CYSP ) mitoxantrone ( DHAD ) etoposide ( VP-16 ) increase response rate duration response adult refractory relapse acute myelogenous leukemia ( AML ) . II . Correlate response treatment presence P-glycoprotein ( P-gp ) multidrug resistance ( MDR ) degree vitro modulation leukemic blast , include CD34+ blast . III . Correlate response presence resistance mechanism , atypical MDR non-P-gp phenotype . IV . Evaluate toxicity treatment AML patient . V. Study effect CYSP DHAD VP-16 pharmacokinetics metabolism , potentially , intracellular drug accumulation . OUTLINE : Randomized study . The following acronym use : CYSP Cyclosporine , NSC-290193 DHAD Mitoxantrone , NSC-301739 VP-16 Etoposide , NSC-141540 Arm I : 2-Drug Combination Chemotherapy . DHAD ; VP-16 . Arm II : 2-Drug Combination Chemotherapy Drug Resistance Inhibition . DHAD ; VP-16 ; CYSP . PROJECTED ACCRUAL : At least 25 patients/arm enter approximately 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myelogenous leukemia ( AML ) follow category : Refractory initial standard therapy consist idarubicin/cytarabine amsacrin/cytarabine ( protocol HOVON 29 ) First subsequent relapse follow complete response standard chemotherapy ( protocols HOVON 4/4A 11 protocol ) At least 6 month mitoxantrone/etoposide relapse No myelodysplasia PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Hematopoietic : Not applicable Hepatic : Bilirubin great 2 x normal Alkaline phosphatase great 2 x normal Renal : Creatinine great 1.7 mg/dl ( 150 micromoles/liter ) OR Creatinine clearance least 60 ml/min Cardiovascular : No uncontrolled hypertension No severe cardiac disease Pulmonary : No severe pulmonary disease Other : No know intolerance study drug No uncontrolled severe infection Not HIV seropositive No severe neurologic metabolic disease No concomitant malignancy except : Nonmelanomatous skin cancer In situ cervical carcinoma No pregnant woman PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>